Patents Assigned to Genentech
  • Patent number: 9611323
    Abstract: The present invention relates to antibodies that bind blood brain barrier receptors (BBB-R) and methods of using the same.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: April 4, 2017
    Assignee: Genentech, Inc.
    Inventors: Mark Dennis, Ryan Jefferson Watts, Yunhua Joy Yu, Yin Zhang
  • Publication number: 20170088582
    Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
    Type: Application
    Filed: May 19, 2015
    Publication date: March 30, 2017
    Applicants: RQX PHARMACEUTICALS, INC., GENENTECH, INC.
    Inventors: Tucker Curran ROBERTS, Peter Andrew SMITH, Robert I. HIGUCHI, Prasuna PARASELLI, Philippe BERGERON, Michael F.T. KOEHLER, Huiyong HU, Jacob Bradley SCHWARZ, Cuong LY, James CRAWFORD
  • Publication number: 20170087137
    Abstract: The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Application
    Filed: December 9, 2016
    Publication date: March 30, 2017
    Applicant: Genentech, Inc.
    Inventors: Anthony Estrada, Wen Liu, Snahel Patel, Michael Siu
  • Publication number: 20170087136
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variablesRA, RAA, subscipt n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: September 23, 2016
    Publication date: March 30, 2017
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe ANDREZ, Paul Robert BICHLER, Chien-An CHEN, Sultan CHOWDHURY, Shannon Marie DECKER, Christoph Martin DEHNHARDT, Thilo FOCKEN, Michael Edward GRIMWOOD, Ivan William HEMEON, Qi JIA, Jun LI, Zhiguo LIU, Daniel F. ORTWINE, Brian SAFINA, Daniel SUTHERLIN, Tao SHENG, Shaoyi SUN, Andrew D. WHITE, Michael Scott WILSON, Alla Yurevna ZENOVA, Jiuxiang ZHU
  • Publication number: 20170091377
    Abstract: Apparatus, systems, computer-readable media, articles of manufacture and methods for selecting an antibody. Apparatus, systems, computer-readable media, articles of manufacture and methods for producing the selected antibody. The selecting may include determining one or more physiochemical characteristics of the antibody. The determining may be based on antibody structural parameters.
    Type: Application
    Filed: May 27, 2016
    Publication date: March 30, 2017
    Applicant: Genentech, Inc.
    Inventors: VIKAS K. SHARMA, TREVOR E. SWARTZ, THOMAS W. PATAPOFF
  • Patent number: 9605065
    Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: March 28, 2017
    Assignee: GENENTECH, INC.
    Inventors: Sek Chung Fung, Matthew Moyle, Mason Lu, Changning Yan, Sanjaya Singh, Dan Huang
  • Patent number: 9605005
    Abstract: The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: March 28, 2017
    Assignee: Genentech, Inc.
    Inventors: Nicole Blaquiere, Georgette Castanedo, Jianwen A. Feng, Baihua Hu, Steven Staben, Po-wai Yuen, Guosheng Wu, Jason Burch
  • Patent number: 9604984
    Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: March 28, 2017
    Assignee: Genentech, Inc.
    Inventors: Mark Edward Zak, Nicholas Charles Ray, Simon Charles Goodacre, Rohan Mendonca, Terry Kellar, Yun-Xing Cheng, Wei Li, Po-Wei Yuen
  • Publication number: 20170081341
    Abstract: Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: December 5, 2016
    Publication date: March 23, 2017
    Applicant: Genentech, Inc.
    Inventors: Nicole Blaquiere, Steven Do, Danette Dudley, Adrian Folkes, Robert Heald, Timothy Heffron, Mark Jones, Aleksandr Kolesnikov, Chudi Ndubaku, Alan G. Olivero, Stephen Price, Steven Staben, Lan Wang
  • Patent number: 9598485
    Abstract: The present invention relates to anti-Tau antibodies, such as antibodies that bind to a phosphorylated epitope on human Tau protein with high specificity and/or affinity, and methods of using the same.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: March 21, 2017
    Assignees: AC IMMUNE S.A., GENENTECH, INC.
    Inventors: Gai Ayalon, Danielle Marie Di Cara, Isidro Hotzel, Andrea Pfeifer, Andreas Muhs, Maria Pihlgren, Oskar Adolfsson
  • Patent number: 9597411
    Abstract: The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: March 21, 2017
    Assignee: Genentech, Inc.
    Inventors: Youjun Chen, William Mallet, Paul Polakis, Christine Tan, Jyoti Asundi, Suzanna Clark
  • Publication number: 20170073424
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: November 2, 2016
    Publication date: March 16, 2017
    Applicant: Genentech, Inc.
    Inventors: Mark Dennis, Bonnee Rubinfeld, Paul Polakis
  • Patent number: 9592235
    Abstract: The invention provides a method of treating cancer in a patient by administering a compound of formula (I): wherein R1 R2 and R3 are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: March 14, 2017
    Assignee: Genentech, Inc.
    Inventors: Huifen Chen, Terry Crawford, Seth F. Harris, Steven R. Magnuson, Chudi Ndubaku, Lan Wang
  • Patent number: 9593167
    Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: March 14, 2017
    Assignee: GENENTECH, INC.
    Inventors: Mark S. Dennis, Bonnee Rubinfeld, Paul Polakis, Aya Jakobovits
  • Publication number: 20170067108
    Abstract: Methods of diagnosing and treating disorders related to excess eosinophil numbers or activity, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.
    Type: Application
    Filed: April 22, 2016
    Publication date: March 9, 2017
    Applicant: Genentech, Inc.
    Inventors: ALEXANDER R. ABBAS, JOSEPH R. ARRON, DAVID F. CHOY, GUIQUAN JIA, NICHOLAS J.I. LEWIN-KOH, KATRINA B. MORSHEAD
  • Patent number: 9586991
    Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: March 7, 2017
    Assignee: GENENTECH, INC.
    Inventors: Frederick Cohen, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui, John A. Flygare
  • Patent number: 9586956
    Abstract: The invention provides novel compounds having the general formula: wherein A, R1 and R2 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: March 7, 2017
    Assignee: Genentech, Inc.
    Inventors: Huifen Chen, Terry Crawford, Steven R. Magnuson, Chudi Ndubaku, Lan Wang
  • Patent number: 9586952
    Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 7, 2017
    Assignee: GENENTECH, INC.
    Inventors: Nicholas D. Smith, Steven P. Govek, Mehmet Kahraman, Celine Bonnefous, Jackaline D. Julien
  • Patent number: 9585956
    Abstract: The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: March 7, 2017
    Assignees: AC IMMUNE S.A., GENENTECH, INC.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Publication number: 20170058049
    Abstract: The invention provides antibodies to specific neural proteins and methods of using the same.
    Type: Application
    Filed: August 11, 2016
    Publication date: March 2, 2017
    Applicant: Genentech, Inc.
    Inventors: Jasvinder Atwal, Yongmei Chen, Cecilia Pui Chi Chiu, Robert A. Lazarus, Weiru Wang, Ryan J. Watts, Yan Wu, Yingnan Zhang